New HIV Preventive Drug Lenacapavir Set for Southern Africa Rollout
Lenacapavir, a newly approved HIV preventive treatment, promises over 99% protection with just two doses annually, marking a significant advancement in public health efforts.
Editorial Staff
1 min read
Updated 1 day ago
The new drug Lenacapavir has been approved after extensive research and is now poised for a mass rollout across Southern Africa. This preventive treatment is administered just twice a year.
With a reported protection rate exceeding 99%, Lenacapavir is expected to play a crucial role in reducing HIV transmission rates in the region.
This initiative reflects ongoing efforts to combat HIV and improve health outcomes, particularly in areas heavily affected by the virus.